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Sex differences and the role of IL-10 in
ischemic stroke recovery
Sarah E. Conway1,2, Meaghan Roy-O’Reilly3, Brett Friedler4, Ilene Staff5, Gilbert Fortunato5
and Louise D. McCullough3*

Abstract
Females experience poorer recovery after ischemic stroke compared to males, even after controlling for age and stroke
severity. IL-10 is an anti-inflammatory cytokine produced by T regulatory cells and Th2 CD4+ helper T cells. In ischemic
stroke, an excessive IL-10 response contributes to post-stroke immunosuppression, which worsens outcomes. However,
it is unknown if sex differences exist in IL-10 levels after ischemic stroke. In this study, we found that higher levels of IL-10
were associated with poor acute and long-term outcomes after ischemic stroke in female patients but not in males. After
controlling for confounders, IL-10 was not an independent predictor of functional outcomes. This suggests that
higher serum IL-10 levels may reflect factors that interact with sex such as age and stroke severity.
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Findings
Introduction

Females experience poorer recovery after ischemic
stroke compared to males, even after controlling for age
and stroke severity [1, 2]. Many factors contribute to this
female disadvantage including the higher prevalence of
comorbidities including hypertension and atrial fibrillation and lower levels of social support, higher rates of
pre- and post-stroke depression and higher pre-stroke
disability levels [3–5]. Emerging evidence suggests that
females may also experience higher rates of post-stroke
immunosuppression [6], which contribute to poorer
acute outcomes [7]. IL-10 is an anti-inflammatory cytokine produced by T regulatory cells and Th2 CD4+
helper T cells [8]. In ischemic stroke, an excessive IL-10
response contributes to post-stroke immunosuppression,
increasing the risk of post-stroke infection and poor outcomes [9]. It is unknown whether sex differences exist in
the IL-10 response after ischemic stroke. However,
others have found sex differences in IL-10 with aging
which prompted this study. IL-10 levels typically decrease with age [10], but this age-related decline in IL-10
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is more prominent in men than in women [11]. In this
study, we investigated the relationship between IL-10
levels and stroke outcomes in males and females.
Methods
Study setting and population

This study was approved by the Hartford Hospital IRB and
was conducted at a regional tertiary care facility, with a
Joint Commission certification as a comprehensive stroke
center. Since 2011, serum from acute ischemic stroke (AIS)
patients who have a known stroke onset time, and who
consent under an IRB-approved protocol to participate
in a biobank study, has been prospectively collected.
Protocol

Serum samples were drawn from 178 patients (76 females
and 102 males) at 24 ± 6 h post-ischemic stroke. Stroke was
defined as an acute-onset focal neurological deficit with
confirmation by radiographic imaging (CT or MRI). Exclusion criteria were history of active malignancy, autoimmune
disease, immunosuppressive treatment, and hemorrhagic
stroke. Cytokine levels were measured using a multiplex
ELISA (BioRad) and measured in pg/mL.
Measurements

The primary outcome measure was in-hospital mortality
or discharge to hospice. Secondary outcome measures
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Table 1 Comparison by sex of patient population
Category

Female

Age, mean (standard deviation)
IL-10 levels, median (IQR) in pg/mL

p

Male

72.934 (14.6709)

64.471 (14.5089)

0.000

8.4 (4.163–11.278)

6.225 (3.81–8.43)

0.014

Stroke risk factor history
Hypertension, %

80.6 %

73.3 %

NS

Heart disease, %

26.4 %

30.0 %

NS

Diabetes, %

29.2 %

25.6 %

NS

Smoking, %

13.9 %

20.2 %

NS

High cholesterol, %

61.1 %

65.6 %

NS

Pre-stroke “good condition”
Baseline modified Barthel ≥ 15, %

93.4 %

80 %

NS

Baseline modified Rankin ≤ 2, %

87.8 %

94.9 %

NS

6 (3, 16.25)

4 (2, 14)

NS

Discharge NIH, median (IQR)

3 (0.25, 4.75)

2.5 (1.00–7.500)

NS

Change in NIH, median (IQR)

−1.00 (−8.00 to 0.00)

−1.00 (−6.00 to 0.00)

NS

14.5 %

6.3 %

NS

Markers of stroke severity
Admission NIH, median (IQR)
Acute outcomes post-stroke

Death in hospital, %
Death or discharge to hospice, %

20.0 %

10.5 %

NS

Discharge to home, %

38.2 %

47.4 %

NS

Modified Barthel ≤ 14, %

25.6 %

20.4 %

NS

Modified Rankin score >2, %

45.0 %

25.9 %

NS

Composite negative outcome, %

40.8 %

23.5 %

0.014

Modified Barthel ≤ 14, %

19.2 %

16.2 %

NS

Modified Rankin score >2, %

32.0 %

25.0 %

NS

Composite negative outcome, %

30.3 %

18.6 %

NS

3-month negative outcomes

12-month negative outcomes

Comparison of age, stroke risk factors, pre-stroke condition, stroke severity, and stroke outcomes between females and males. Females had higher IL-10 levels,
were significantly older, and had worse composite 3-month outcomes compared to males. A composite negative outcome was defined as death or disabled with
a modified Rankin score greater than 2 or a modified Barthel score less than or equal to 14

included modified Rankin score (mRS) at 3 and 12 months,
modified Barthel index (MBI) at 3 and 12 months, mortality at 3 and 12 months, composite negative outcome (death
or MBI ≤ 14 or mRS > 2) at 3 and 12 months, and rate of
post-stroke infection.
Table 2 Acute stroke outcomes and median IL-10 levels in
males and females
Alive and no hospice,
median (IQR)
Males
Females

Death or discharge to hospice,
median (IQR)

NS

NS

5.97 (3.43–10.13)*

10.33 (8.8–23.54)*

*p <0.05
IL-10 levels were not different between males who died or went to hospice
and those who survived their hospital stay and were not discharged to
hospice. Females who died or went to hospice had higher median IL-10 levels
at 24 h post-stroke compared to those females who survived their hospital
stay and were not discharged to hospice

Statistical analysis

Univariate analyses were conducted on IL-10 levels. The
Wilcoxon ranked sum test was used to compare IL-10
levels between groups, which were dichotomized for outcome measures. For acute outcomes, IL-10 levels were
compared between patients who were discharged to
hospice or died with those who survived their hospital
stay and were discharged to home or rehab. For 3- and
12-month outcomes, patients were dichotomized into two
groups defined as “composite negative outcome” and “composite positive outcome.” Composite negative outcome was
defined as death or MBI ≤ 14 or mRS > 2 at 3 and
12 months, while composite positive outcome was defined
as alive and MBI > 15 or mRS ≤ 2. The MBI measures performance in activities of daily living and is based on physical disability, while the mRS is a function-based scale
measuring overall disability and level of independence.
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Table 3 Stroke severity on admission and median IL-10 levels in
males and females
Mild,
median (IQR)
Males
Females

Moderate,
median (IQR)

Table 5 Twelve-month stroke outcomes and median IL-10
levels between males and females

Severe,
median (IQR)

NS

NS

NS

6.12 (3.41–9.72)*

7.29 (3.75–10.3)*

9.79 (6.95–17.48)*

Composite positive,
median (IQR)

Composite negative,
median (IQR)

NS

NS

6.795 (3.6–9.99)*

9.41 (7.51–14.83)*

Males
Females

*p <0.05
Median IL-10 levels at 24 h post-stroke were not different between males
with differing stroke severity. Females who had more severe strokes had
higher median IL-10 levels at 24 h post-stroke compared to those females
who had less severe strokes

*p <0.05
Median IL-10 levels between male patients with composite positive and
composite negative 12-month outcomes did not differ. Median IL-10 levels
were higher in female patients with composite negative 12-month outcomes when
compared to female patients with composite positive 12-month outcomes

The Kruskal-Wallis test was used for stroke severity,
which was trichotomized into mild (National Institutes of
Health Stroke Scale (NIHSS) < 3), moderate (NIHSS greater
than 3 and less than 10), and severe (NIHSS greater than or
equal to 10). Stroke risk factors, medication usage, stroke
severity measures, and acute and 3- and 12-month outcomes were compared between sexes using chi-square tests
of proportion, Wilcoxon ranked sum test for ordinal scales
(NIH, change in NIH), and t-test for age. Significant findings identified in the univariate analyses were included
in a multivariate logistic regression to control for significant confounders. The criterion of statistical significance was set at 0.05.

Multivariate logistic regression analyses were conducted
predicting the key outcomes. IL-10 was entered as a continuous predictor following a logarithmic transformation to
normalize its distribution; other covariates included age,
stroke severity at admission (as measured by NIHSS), heart
disease, and high cholesterol.
After controlling for confounders, IL-10 was not independently associated with mortality or post-stroke
functional outcomes in either sex.

Results

Our study found no significant sex differences with
regards to modifiable stroke risk factors, pre-stroke
functional condition, stroke severity, or acute mortality
(Table 1). Female stroke patients had higher levels of
IL-10 compared to males (p = 0.014) (Table 1). Interestingly, in our cohort, as has been seen by others, females were significantly older and were more likely to
have a composite negative outcome at 3 months when
compared to males (Table 1).
An association between higher levels of IL-10 and risk
of death or discharge to hospice was found in female patients (p = 0.018), but was not seen in males (Table 2). In
addition, there was a female-specific association between
higher IL-10 levels and stroke severity on admission (p
= 0.049) (Table 3), composite negative outcome at 3 (p =
0.035) and 12 months (p = 0.022) (Tables 4 and 5), and
post-stroke urinary tract infection (p = 0.003) (Table 6).
Table 4 Three-month stroke outcomes and median IL-10 levels
between males and females

Males
Females

Composite positive,
median (IQR)

Composite negative,
median (IQR)

NS

NS

6.89 (3.43–10.24)*

8.96 (6.26–13.37)*

*p <0.05
Median IL-10 levels between male patients with composite positive and
composite negative 3-month outcomes did not differ. Median IL-10 levels were
higher in female patients with composite negative 3-month outcomes when
compared to female patients with composite positive 3-month outcomes

Discussion/conclusion

Higher IL-10 levels measured at 24 h post-stroke were
associated with poor acute and long-term outcomes in
females only, which may be in part due to the older age
of females in this cohort compared to males. After controlling for other known predictors of stroke outcomes
in a multivariate analysis, levels of IL-10 were not independently associated with outcomes in females or in
males. This suggests that IL-10 is related to other factors
that affect stroke outcome, likely stroke severity or age.
In larger cohorts, women do have poorer outcomes
even after controlling for age in multivariable models;
however, our cohort was too small to statistically control
for age. Mortality may differ depending on the cohort
examined as recent data from Chinese and Danish populations suggest that elderly women have more severe strokes
but potentially lower mortality than men [12, 13]. However,
most of the available literature suggests that in patients that
do survive their stroke, recovery is poorer and incomplete
in women [2, 12].
Studies have shown that IL-10 decreases with age [10]
and that females experience less of the age-related decrease in IL-10 than males as they age [11]. The females
Table 6 Post-stroke UTI and median IL-10 levels between males
and females
Males
Females

No-UTI, median (IQR)

Yes-UTI, median (IQR)

NS

NS

6.795 (3.71–9.98)**

10.01 (8.96–16.93)**

**p<0.01
Median IL-10 levels between patients with urinary tract infection (UTI) and
without UTI were significantly different in females but not in males. Females
who developed post-stroke UTIs had higher levels of IL-10 than those who did
not develop urinary infections
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in our study cohort were significantly older than the
males, which may in part explain their higher IL-10
levels. Sex differences in IL-10 have been reported both
in mice and in humans. A study by Banerjee et al.
showed that female mice had an increase in a subset of
IL-10 secreting CD8+ T cells after stroke, which was not
seen in male mice [14]. Others have found that in agematched adult female and male mice subjected to cardiac
ischemia and reperfusion injury that females had increased
IL-10 mRNA expression vs. males [15], similar to that seen
in female stroke patients in this study. Other clinical studies
in patients with sepsis found that females had increased levels of IL-10 and lower levels of TNF-α (a
pro-inflammatory cytokine) when compared to males
[16], suggesting a more robust IL-10 response in
women. IL-10 has been studied in experimental stroke
models, and levels are time-dependent. One study
showed that IL-10 levels were significantly lower at 6 h
in stroke mice compared to sham mice but were increased at 24 and 72 h post-stroke; however, only male
animals were examined [17]. We only investigated
levels at one time point after stroke and may have
missed the peak IL-10 response. Future studies will
need to determine the time course of IL-10 after stroke
in both men and women. IL-10 levels also have been
found to differ with stroke etiology. A study by Arponen et
al. found that ischemic stroke patients with high-risk
sources for cardioembolism had higher levels of IL-10 when
compared to those with strokes due to large vessel disease/
atherosclerosis [18]. Since more women than men have
cardioembolic strokes (men are more likely to have
atherosclerotic events) [19], this mirrors the IL-10
levels found in our cohort.
Interestingly, in our study, IL-10 levels were higher in
females who developed post-stroke UTIs versus those females who did not, and this association was not seen in
males. In experimental models of brain ischemia, poststroke infections have been associated with the activation of
the autonomic nervous system and neuroendocrine pathways, which activate anti-inflammatory signaling pathways,
including IL-10 [20]. In addition, studies have shown that
stroke severity is one of the strongest determinants of poststroke infection risk [20, 21]. In our cohort, males and females had statistically similar stroke severity. Thus, it is
likely that the immunosuppressive effect of IL-10 poststroke affects females differently than males, and this topic
merits further investigation.
The main limitation of this study was its small sample
size. Thus, this study was likely underpowered to detect
an independent association between IL-10 and stroke
outcomes by sex. Larger cohorts are needed to confirm
these findings and to investigate the relationship between IL-10, stroke outcomes, and post-stroke infection.
Understanding sex differences in stroke is critical as
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there are chronological and physiological differences in
the way females and males suffer and react to ischemic
damage, especially with regard to aging-related immune
changes. Developing a better understanding of these differences is important in order to develop sex-specific
immunomodulatory therapies.
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